Cohance Lifesciences Stock Plummets to New 52-Week Low at Rs. 609.1

Cohance Lifesciences has reached a new 52-week low, hitting Rs. 609.1 on November 17, 2025. This marks a significant decline for the small-cap pharmaceutical and biotechnology company, which has seen its stock price fall by 28.35% over the past 13 consecutive trading days. The stock has underperformed its sector by 0.48% today, reflecting broader market trends. In terms of performance metrics, Cohance Lifesciences has struggled over the past year, with a staggering decline of 52.18%, contrasting sharply with the Sensex's positive performance of 9.21% during the same period. The company's operating profit growth has been modest, averaging just 4.15% annually over the last five years, and recent financial results have shown a decline in key indicators such as operating cash flow and profit before tax. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent downward trend. With 100% of promoter shares pledged, the stock faces additional pressure in a declining market. Overall, Cohance Lifesciences is navigating a challenging landscape, marked by significant price declines and underperformance relative to its peers.